Molecular diagnosis of central nervous system opportunistic infections and mortality in HIV-infected adults in Central China

Rongrong Yang††, Hong Zhang††, Yong Xiong†*, Xien Gui†, Yongxi Zhang†, Liping Deng†, Shicheng Gao†, Mingqi Luo†, Wei Hou‡ and Deyin Guo‡

Abstract

Background: CSF PCR is the standard diagnostic technique used in resource-rich settings to detect pathogens of the CNS infection. However, it is not currently used for routine CSF testing in China. Knowledge of CNS opportunistic infections among people living with HIV in China is limited.

Methods: Intensive cerebrospinal fluid (CSF) testing was performed to evaluate for bacterial, viral and fungal etiologies. Pathogen-specific primers were used to detect DNA from cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6) and John Cunningham virus (JCV) via real-time polymerase chain reaction (PCR).

Results: Cryptococcal meningitis accounted for 63.0% (34 of 54) of all causes of meningitis, 13.0% (7/54) for TB, 9.3% (5/54) for Toxoplasma gondii. Of 54 samples sent for viral PCR, 31.5% (17/54) were positive, 12 (22.2%) for CMV, 2 (3.7%) for VZV, 1 (1.9%) for EBV, 1 (1.9%) for HHV-6 and 1 (1.9%) for JCV. No patient was positive for HSV. Pathogen-based treatment and high GCS score tended to have a lower mortality rate, whereas patients with multiple pathogens infection, seizures or intracranial hypertension showed higher odds of death.

Conclusion: CNS OIs are frequent and multiple pathogens often coexist in CSF. Cryptococcal meningitis is the most prevalent CNS disorders among AIDS. The utility of molecular diagnostics for pathogen identification combined with the knowledge provided by the investigation may improve the diagnosis of AIDS related OIs in resource-limited developing countries, but the cost-efficacy remains to be further evaluated.

Keywords: AIDS, Central nervous system diseases, Cerebrospinal fluid

Background

Central nervous system (CNS) infectious is a major cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) [1, 2]. Symptomatic neurological diseases happened in about 40–70% of HIV/AIDS patients during the course of their illness [1], and about 10–20% HIV/AIDS patients have neurologic symptoms as an initial manifestation [2, 3]. Studies indicated that opportunistic infections are the most common causes of neurologic diseases in HIV/AIDS patients in developing countries [4–8]. In China, lumbar puncture (LP) is a routine practice and cerebrospinal fluid (CSF) is commonly collected for patients with suspected diagnosis of CNS infection. However, the available and frequently-used means of diagnosis are generally limited to CSF routine and biochemical tests, Gram stain, India ink stain, cryptococcal antigen (CrAg) detection, and bacterial/fungal cultures. As a result, country-specific data in our hospital regarding prevalence of CNS disorders are sparse, and many patients remain misdiagnosed and inadequately treated.

In resource-rich settings, the standard diagnostic technique used to identify the presence of viral, parasitic, and
specific bacterial infection of the CNS disorders is CSF polymerase chain reaction (PCR); however, in China in HIV-infected patients, CSF PCR is not currently used for routine tests. The prevalence data regarding CNS infectious diagnosed via PCR in China was particularly absent at present. In this study, CSF samples were tested for CMV, HSV, VZV, EBV, HHV-6 and JCV via PCR. The prevalence of CNS OIs in HIV-infected Chinese adults and their impact on patient outcomes were determined.

**Methods**

**Patients population**

This hospital-based study was conducted at Zhongnan Hospital of Wuhan University, China, between 1 December 2012 and 30 September 2014. Patients were eligible for the study if they had: (1) confirmed with HIV infection; (2) three or more symptoms of meningitis and/or encephalitis (headache, seizure, nausea/vomiting, alteration in consciousness, photophobia, or a focal neurological deficit); and (3) agreed to do a lumbar puncture (LP), as determined by the attending physician. Exclusion criteria for enrollment included: (1) patients with delirium, such as sepsis due to a non-neurological infection or metabolic abnormality; (2) patients with peripheral neuropathy and psychosis rather than medical explanation for their symptoms; or (3) patients with a documented immunosuppressive except for HIV infection or neurological illness. Meningitis was diagnosed if there was a combination of meningeal irritation symptoms and signs and the presence of more than five white blood cells in CSF obtained by lumbar puncture. Exclusion criteria included malignancies, various inflammatory conditions, sarcoidosis, and infectious secondary to procedures. Meningoencephalitis was defined as any brain parenchymal involvement (e.g., seizures), behavioral change, confusion, dysphasia and other cortical deficits, with signs of meningeal irritation. Encephalitis was defined as fever with altered sensorium with CSF pleocytosis and raised protein with or without focal neurological signs in whom malaria, bacterial or fungal meningitis were excluded. Trained radiologists and neurologists were also invited to help identifying patients with a suspected diagnosis of meningitis, encephalitis or meningoencephalitis. The study was approved by Zhongnan Hospital of Wuhan University Ethics Committee.

Demographic information, such as age, gender, marital status, risk factors, duration between HIV infection and hospital admission, clinical features and past medical history were collected on a standardized report form by the trained physician. In China, lumbar puncture (LP) is routine practice for patients with a suspected CNS infection prior to antibiotic treatment. Other important medical assessment were computed tomography (CT) or magnetic resonance imaging (MRI) for patients with a focal brain lesion or suspected brain hemorrhage. But whether the imaging examination ultimately used depends on the patients’ or their family members’ willingness and attitude.

**CSF testing**

All CSF samples were collected via lumbar puncture and stored at −20 °C for molecular diagnostics. DNA was isolated by using the easyMAG Instrument (bioMérieux). Primers amplifying a conserved sequence of viral DNA polymerase (BALF5) gene and a fluorogenic probe were used at a primer concentration of 0.9 μM and a probe concentration of 0.25 μM. Amplification was carried out in an ABI PRISM 7900 HT Sequence Detector (PE Applied Biosystems) and the standard curve was created with Sequence Detection System software by plotting the CT values against known CMV, EBV, JCV, VZV, HHV-6, HSV or TB-DNA concentrations. The assay has a detection limit of 500 genome equivalents/ml.

**Statistical analysis**

Continuous data are presented as mean ± standard deviation (for normally distributed variables) or median and interquartile range or IQR (for variable influenced by extreme values). Categorical data are presented as numbers with proportions. P-values were 2-sided and considered statistically significant if <0.05. Statistical analyses were performed using SPSS for Windows, version 19.0 (SPSS, Chicago, IL).

**Results**

**Patient characteristics**

In this study, 57 patients with CNS diseases out of 658 hospitalized AIDS (≥14 years old) were admitted to Zhongnan Hospital of Wuhan University with a complaint of new or recurrent neurological or psychiatric symptoms were included (Fig. 1). Of these 57 patients, complete clinical information was available in 54 (94.7%). Forty-one cases of meningitis, six cases of encephalitis and seven cases of meningoencephalitis were found in this series. Characteristics of the 54 patients are shown in Table 1. The mean age was 38 years and 64.8% of participants were male. The main occupational population was farmer (70.4%). And the main HIV acquisition route was sexual contact (79.6%). At the time of enrollment, a median duration of 45 days was observed. The median CD4+ T cell count was 31 cells/μl.

**Pathogen(s) detecting in CSF**

Pathogens were detected in 47 (87.0%) CSF samples. The number of patients diagnosed with one or more pathogens is shown in Table 2. *Cryptococcus neoformans* was
the most common pathogen found (63.0%) and the most common copathogen (22.2%). There were high rates of detection of CMV (22.2%) and tuberculosis (13.0%). We also detected VZV (3.7%), JCV (1.9%), EBV (1.9%) and HHV-6 (1.9%) in this patient population. No case of HSV were detected by PCR.

Results of PCR positive pathogen(s) detected by other methods
Of the 34 cases with cryptococcus, three were negative on India Ink (8.8%), and four were negative on CrAg (11.8%).

Of five PCR diagnosed toxoplasmosis in this series, all responded clinically and radiographically within four weeks of initiation of pyrimethamine and clindamycin combination therapy.

Among the 12 CMV-DNA positive patients, 8 (66.7%) serum samples were negative for CMV-DNA and the average level of CMV-DNA in CSF was $2.80 \pm 1.15 \log_{10}\text{copies/ml}$.

Among five patients diagnosed toxoplasmosis, brain CT or MRI was used for four patients. The representative ring enhancing lesions were found in all the four patients. For the EBV-DNA positive patient, mass lesions were not found. For the JCV-DNA positive patient, typical

---

**Table 1** Patient demographics (N = 54)

| Feature                              | No (%)        |
|--------------------------------------|---------------|
| Age (years), mean (SD)               | 38 (11.2)     |
| Male                                 | 35 (64.8)     |
| Occupation                           |               |
| Farmers                              | 38 (70.4)     |
| Clerk                                | 8 (14.8)      |
| Businessman                          | 4 (7.4)       |
| Others                               | 4 (7.4)       |
| HIV transmission route               |               |
| Sex                                  | 43 (79.6)     |
| Blood donation/transfusion            | 6 (11.1)      |
| IDU                                  | 2 (3.7)       |
| Unknown                              | 3 (5.6)       |
| Days since HIV diagnosis, median (IQR)| 45 (1–732)   |
| CD4$^+$ T cells/µl, median (IQR)     | 31 (21–83)    |

SD standard deviation

---

**Table 2** Characteristics of patients with CSF pathogen(s)

| Pathogens | Individual CSF prevalence | 1 pathogen | No. of cases | 2 pathogens | No. of cases | 3 pathogens | No. of cases |
|-----------|---------------------------|------------|--------------|-------------|--------------|-------------|--------------|
| Crypto$^a$| 34/54 (63.0%)             | Crypto     | 22           | Crypto/CMV  | 7            | Crypto/TB/CMV | 2            |
| CMV       | 12/54 (22.2%)             | CMV        | 2            | Crypto/VZV  | 1            | Crypto/TB/HHV-6 | 1            |
| TB        | 7/54 (13.0%)              | TB         | 3            | Crypto/JCV  | 1            | CMV/TB      | 1            |
| Toxop     | 5/54 (9.3%)               | Toxop      | 5            |             |              |             |              |
| VZV       | 2/54 (3.7%)               | VZV        | 1            |             |              |             |              |
| JCV       | 1/54 (1.9%)               | JCV        | 0            |             |              |             |              |
| EBV       | 1/54 (1.9%)               | EBV        | 1            |             |              |             |              |
| HHV-6     | 1/54 (1.9%)               | HHV-6      | 0            |             |              |             |              |
| HSV       | 0/54 (0%)                 | HSV        | 0            |             |              |             |              |
| Total     | 63 pathogens              | 34/54 (63.0%) | 10/54 (18.5%) | 3/54 (5.6%) |             |             |              |
white matter changes were found, which was consistent with the PCR for JCV.

Among 12 CMV-DNA positive patients, brain CT or MRI was used for 6 patients and none was found with brain parenchymal lesion.

Risk factors associated with mortality
In our study population, the total mortality rate was 22.2% (12/54). Table 3 summarizes the potential risk factors of death in our study population. The odds of death together with 95% confidence intervals were reported for each covariate. In the multivariate analysis, pathogen-based treatment and high glasgow coma scale (GCS) score were associated with lower odds of death. Conversely, patients with multiple pathogens infection, seizures or intracranial hypertension showed higher odds of death.

Discussion
This hospital-based study provides information about the spectrum of pathogens causing CNS infections and mortality among people living with HIV in Zhongnan Hospital of Wuhan University in central China. The spectrum of HIV-associated central nervous system disorders may be influenced by differences in the epidemiology.

We identified a microbiologic diagnosis for clinical meningitis in a cohort of HIV-infected Chinese inpatients. Our data suggested that the most common pathogen causing meningitis is Cryptococcus neoformans. The most common viral pathogen causing meningitis is CMV and that the most common bacterial pathogen is TB. Our finding highlighted the utility of molecular diagnostics for improving pathogen identification for CNS infections.

The HIV epidemic has caused a marked increase in cases of cryptococcal meningitis such that it has become the leading cause of meningitis among patients living with HIV [9–11]. We found that cryptococcal meningitis caused the majority of meningitis among hospitalized AIDS patients, which accounted for 63.0% of all causes of meningitis in this study. In a review, the total cryptococcal meningitis prevalence was 52.0% in sub-Saharan Africa [12]. Our relatively high prevalence may be attributable to different methodologies and tests used for assessing prevalence; differences in host factors; or geographic variations in the epidemiology of cryptococcal meningitis.

The prevalence of toxoplasma gondii in this study are higher than previously reported from a study in Zambian [13]. In our study population, the median CD4+ T-cell count was 31 cells/μl and all were newly diagnosed with HIV and without any prophylaxis treatment, whereas in Zambian [13] study, the enrollment CD4+ T-cell count was 81 cells/μl in men and 99 cells/μl in women, and 118 (35.6%) patients were on cART for a median duration of 240 days. The patient population and the presence of anti-Toxoplasma treatment may account for the high present of *Toxoplasma gondii*.

### Table 3 Variables associate with death in univariate and multivariate analysis

| Variable                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | Odds ratio (95% CI) | P value               | Odds ratio (95% CI) | P value   |
| Categorical                     |                     |                       |                      |
| Male                            | 0.58 (0.30–1.32)    | 0.26                  |                       |           |
| cART status                     | 0.48 (0.30–2.22)    | 0.56                  |                       |           |
| Multiple pathogens              | 0.33 (0.14–0.56)    | <0.0001               | 0.46 (0.26–0.74)      | 0.002     |
| Cryptococcal meningitis         | 1.32 (0.80–2.34)    | 0.22                  |                       |           |
| CMV                             | 1.21 (0.58–2.33)    | 0.74                  |                       |           |
| Tuberculosis                    | 0.63 (0.38–1.26)    | 0.30                  |                       |           |
| EBV                             | 0.70 (0.44–1.33)    | 0.23                  |                       |           |
| Other pathogens                 | 0.85 (0.44–1.63)    | 0.53                  |                       |           |
| Pathogen-based treatment        | 5.7 (2.0–17.6)      | <0.0001               | 4.8 (2.4–16.5)        | 0.001     |
| Seizures                        | 0.87 (0.33–1.42)    | 0.08                  | 0.52 (0.36–0.98)      | 0.04      |
| Intracranial hypertension       | 0.27 (0.18–0.84)    | 0.04                  | 0.33 (0.22–0.84)      | 0.03      |
| Disturbance of consciousness    | 0.67 (0.43–1.04)    | 0.06                  | 1.00 (0.46–2.18)      | 0.99      |
| Continuous                      |                     |                       |                      |
| Age                             | 0.36 (0.14–0.89)    | 0.08                  | 0.56 (0.32–1.02)      | 0.25      |
| GCS                             | 0.22 (0.12–0.32)    | <0.0001               | 0.42 (0.21–0.80)      | 0.001     |
| CD4 count                       | 0.66 (0.45–1.24)    | 0.68                  |                       |           |

GCS Glasgow coma scale
Cytomegalovirus is a ubiquitous agent that can cause infection at any time during the course of life and commonly infects individuals from diverse geographical and socio-economic backgrounds [14, 15]. By serology, a study reports that 93.9% of the HIV infection patients were positive for anti-CMV IgG antibody [16]. But in most patients, the diseases caused by CMV is so mild that it is overlooked. AIDS patients are commonly positive for CMV when sick with other illnesses. Diagnosis of CMV infection from tissue biopsies is considered the gold standard with specificity for histopathological evaluation near 100% but with low sensitivity (23.2%) [17]. In this study through PCR for CMV-DNA, 12 out of 54 (22.2%) CSF samples were positive. Whether the CMV is truly pathogenic or simply an innocent bystander remains to be further identified. Among the 12 patients with CMV-DNA positive in CSF, 8 (66.7%) serum samples were negative for CMV-DNA and the average level of CMV-DNA in CSF was 2.80 ± 1.15 Log_{10} copies/ml. Among 12 CMV-DNA positive patients, brain CT or MRI was used for six patients. None patient was found with brain parenchymal lesion. These features supported a low CMV burden which is combination with the negative PCR in the blood favored the argument of CMV being a bystander. Neuroimaging was not obtained as part of this study. Therefore, we speculated that EBV might be a non-pathogenic marker of immunodeficiency, being shed from activated B-cells trafficking into the CSF during meningitis. Further investigation on the significance of EBV in the CSF is needed. Quantitative and comparison values from the CSF and serum is necessary to distinguish those with CNS lymphoma from those with non-pathogenic presence of EBV.

HIV strain and host susceptibility factors were thought to be less tendentious to infection by JCV, the pathogen of progressive multifocal leukoencephalopathy (PML). Indeed, the JCV CSF-positive patient had neurological symptoms consistent with PML. The sole JCV-DNA positive patients received brain imaging examination, white matter changes were found, which was consistent with the PCR for JCV.

Seroprevalence of CNS HSV infection has previously been documented at 47.2% in an urban Zambian population [20]. However, HSV DNA was not detected in any CSF samples in our study population. This is likely because the sample in our series is small and because our study used a different detection method (HSV-DNA PCR in CSF) as the Zambian population [20] (HSV IgG ELISA in serum). In our study population, the total mortality rate was 22.2% (12/54). This rate of mortality is lower than reported in Zambian at the beginning of the AIDS epidemic [13]. Our study was not designed for long-term follow-up. It is possible that death occurred in the post-hospitalization period due to loss of follow-up, poor compliance with treatment, and poor access to emergency health services. As expected, the actual mortality rate was higher than 22.2%.

Our study shows that numerous pathogens can be found in the CSF of HIV-infected patients presenting with neurological symptoms in China, and the mortality of this population is very high. There was a high prevalence of co-infection in the CSF, indicative of severe immunodeficiency in this population. This finding warrant a more in dept study in the future since in resource-limited settings, patients present with advanced immunodeficiency and the high morbidity and mortality associated with this condition will continue to bring great challenges to clinicians. Multiple pathogens infection in CNS disorder patients will be an important topic to assess with further study in larger cohorts and with subsequent validation of results.

Diagnostic testing for a broad array of CSF pathogens may be helpful in resource-limited settings to avoid unnecessary treatments and achieve better prognosis. For TB diagnosis, the Xpert MTD/RIF assay is a fully automated nucleic acid amplification testing (NAAT) that can deliver a result for MTB and rifampin resistance in about 2 h. On the basis of studies in countries with high tuberculosis burden, Xpert has been endorsed...
by the World Health Organization and widely deployed [21–28]. In contrast to other NAATs, Xpert can be performed on-demand by personnel with minimal training [28, 29]. The present study supports assessing whether Xpert implementation in the United States is efficient and cost-effective [30]. Therefore, in resource-limited countries, establishment of Xpert is one of the ways to attempt improving the clinical diagnosis level about TB infection in CNS among AIDS patients.

Our study had some limitations. First, the generalizability of our research finding is limited. Since our hospital is the sole comprehensive hospital well-known for AIDS treatment in Hubei province, we can make some general assumptions regarding CNS infection in a province in China. Second, the number of specific pathogens for PCR testing was limited and there are other possible etiologies of CNS infections, but were not assessed in our study. Last but not least, the detection samples associated with the study were limited to CSF, which may be incomplete for diagnosis since pathogens can present in the CSF transiently. For many types of CNS infections, serologic detection on the presence of virus-specific IgM antibodies in serum or a rise in antibody titer can be useful; this study did not include serologic assays.

In this series, in addition to the molecular testing, Cryptococcus can be diagnosed with India Ink and CrAg, TB can be diagnosed with Xpert, and Toxoplasmosis can frequently be managed using an empirical strategy. Meanwhile, some pathogens such as EBV and JCV have no specific, effective treatment, while others such as CMV and HHV-6 require specialized therapies that are frequently unavailable in a resource limited setting. Disease burden, economic pressure, health resource and severity of diseases are critical factors which can effect the cost-efficacy of running a molecular laboratory. In China, we believed that the molecular testing can only be recommended under conditioned circumstances, rather than prioritized under all circumstances.

In conclusion, this study provides baseline data regarding the etiology distribution of CNS infections among hospitalized patients living with HIV/AIDS in a comprehensive Chinese hospital. It reported that the most etiology was cryptococcal meningitis (63.0%). Even as high as 22.2% of CMV DNA positive rate was found in this study, more than half were proved to be an innocent bystander. During periods of severe immunosuppression, AIDS patients with unrecognized CNS opportunistic infections are at high risk of death; thus, efforts should be focused in improving rates of pathogen diagnosis in this vulnerable group. CSF PCR, which is the standard diagnostic technique used in resource-rich settings to detect etiology infections of the CNS, is not currently used for suspected CNS disorder patients in China. Due to limited resources, whether CSF PCR should be prioritized needs to consider the patients’ economic ability.

Abbreviations
CNS: central nervous system; AIDS: acquired immunodeficiency syndrome; CMV: cytomegalovirus; EBV: Epstein-Barr virus; JCV: JC polyomavirus; VZV: varicella-zoster virus; HHV-6: human herpesvirus 6; HSV: herpes simplex viruses; CSF: cerebrospinal fluid.

Authors’ contributions
RRY, HZ and YX devised the study, advised on data analysis and participated in interpreting the data and reviewing the manuscript. XE, YXZ, LPD, SCG and MQL advised on data analysis and participated in interpreting the data and reviewing the manuscript. WH and DYG participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan 430071, China. 2 Basic Medical College of Wuhan University, Wuhan, China.

Funding
This study was supported by the National Science and Technology Major Project of China (2014ZX10001003).

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article and in Fig. 1.

Ethics approval and consent to participate
This clinical study was conducted according to the principles expressed in the Declaration of Helsinki. The ethics committee of Zhongnan Hospital of Wuhan University approved the study and patient confidentiality was maintained by de-identification of patient data and use of a unique ID number for each patient.

Written consent forms were obtained from the patients after gave them appropriate information.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 18 January 2017 Accepted: 20 April 2017

Published online: 02 May 2017

References
1. Weisberg LA. Neurologic abnormalities in human immunodeficiency virus infection. South Med J. 2001;94(3):266–75.
2. Levy RM, Breeden DE. Central nervous system dysfunction in acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1988;1(1):41–64.
3. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology. 2001;56(2):257–60.
4. Bhgjlee AI, Naidoo K, Patel VB, Govender D. Intracranial mass lesions in HIV-positive Patients-the KwaZulu/Natal experience. Neuroscience AIDS Research Group. S Afr Med J. 1999;89(12):1284–8.
5. Fragoso YD, Mendes V, Adamo AP, Bosco LP, Tavares CA. Neurologic manifestations of AIDS: a review of fifty cases in Santos, Sao Paulo, Brazil. Sao Paulo Med J. 1998;116(3):171–20.

6. Isezuo SA, Sani AZ, Ezuzu E, Mayaki S, Njoku CH, Obembe A. Clinical neuropathy in HIV/AIDS: an eight-year review of hospitalized patients in Sokoto, northwestern Nigeria. Trop Doct. 2009;39(3):133–5.

7. Modi M, Mochan A, Modi G. Management of HIV-associated focal brain lesions in developing countries. QJM. 2004;97(7):413–21.

8. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007. p. 10–38.

9. Bekondi C, Bernede C, Passone N, Minssart R, Kamalo C, Mbolidi D, et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis. 2006;10(5):387–95.

10. Cohen DB, Zijlstra EE, Mukaka M, Reiss M, Kamphambale S, Pai M, et al. Diagnosis of cryptococcal and tuberculous meningitis in a resource-limited African setting. Trop Med Int Health. 2010;15(8):910–7.

11. Bisson GP, Lukes J, Thakur R, Mtoni I, MacGregor RR. Cryptococcus and lymphocytic meningitis in Botswana. S Afr Med J. 2008;98(9):724–5.

12. Veltman JA, Bristow CC, Klausner JD. Meningitis in HIV-positive patients in sub-Saharan Africa: a review. J Int AIDS Soc. 2014;17:19184.

13. Siddiqi OK, Ghebremichael M, Dang X, Atadzhanov M, Kaonga P, Khoury MN, et al. Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults. Clin Infect Dis. 2014;58:1771–7.

14. Akinbami AA, Akamnu AS, Adeyemo TA, Wright KO, Dada MO, Dosunmu AO. Cytomegalovirus anti-bodies among healthy blood donors at Lagos University Teaching Hospital. S Afr Med J. 2009;99(7):528–9.

15. Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovirus(CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest. 1998;101:497–502.

16. Fowotade A, Okonko IO, Agbede OO, Suleiman ST. High seropositivity of IgG and IgM antibodies against cytomegalovirus (CMV) among HIV-1 seropositive patients in Ilorin. Nigeria. Afr Health Sci. 2015;15(1):1–9.

17. Kotler DP, Reka S, Borchic A, Cronin WJ. Detection, localization, and quantitation of HIV-associated antigens in intestinal biopsies from patients with HIV. Am J Pathol. 1991;139:823–30.

18. Manzardo C, Del Mar Ortega M, Sued O, Garcia F, Moreno A, Miro JM. Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J Neurovirol. 2005;11(suppl 3):72–82.

19. Kelly MJ, Benjamin LA, Cartwright K, et al. Epstein-Barr virus coinfection in cerebrospinal fluid is associated with increased mortality in Malawian adults with bacterial meningitis. J Infect Dis. 2012;205:106–10.

20. Weiss HA, Buve A, Robinson NJ, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS. 2001;15(suppl 4):S97–108.

21. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2014;44(2):435–46.

22. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;4:CD009593.

23. World Health Organization. Tuberculosis diagnostics: Xpert MTB/RIF test. http://www.who.int/tb/publications/Xpert_factsheet.pdf. Accessed 21 Nov 2014.

24. Zwerling A, White RG, Vassall A, Cohen T, Dowdy DW, Houben RM. Modeling of novel diagnostic strategies for active tuberculosis—a systematic review: current practices and recommendations. PLoS ONE. 2014;9:e110558.

25. Langley L, Lin HH, Squire SB. Cost-effectiveness of Xpert MTB/RIF and investing in health care in African. Lancet Glob Health. 2015;3:e83–4.

26. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13:349–61.

27. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis. 2014;14:2.

28. Zwerling A, White RG, Vassall A, Cohen T, Dowdy DW, Houben RM. Modeling of novel diagnostic strategies for active tuberculosis—a systematic review: current practices and recommendations. PLoS ONE. 2014;9:e110558.

29. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampicin resistance. N Engl J Med. 2010;363:1005–15.

30. Cowan JF, Chandler AS, Kracen E, Park DR, Wallis CK, Liu E, Song C, Persing DH, Fang FC. Clinical impact and cost-effectiveness of Xpert MTB/RIF testing in hospitalized patients with presumptive pulmonary tuberculosis in the United States. Clin Infect Dis. 2017;64(4):482–9.